RaQualia Group R&D Meeting on 21st July

News release Download PDF

Kanagawa, Japan, 10th Jun 2024 – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on targeted protein degradation has become wholly owned consolidated subsidiary of RaQualia Pharma Inc. (TSE: 4579, “RaQualia”) since this March. FIMECS will present at the RaQualia Group R&D Meeting on 21st July.

Date 21st July 2024 (Sun), 13:00-14:30
Presenter Katsuhiro Uto, Ph.D. (Board of Director, RaQualia)

Yusuke Tominari, Ph.D. (CEO, FIMECS)

Kanae Gamo, Ph.D. (CSO, FIMECS)

Place Nihonbashi Life Science Hub <Access>
Fee Free
Capacity 80
Registration Deadline 28th June 2024 (Fri), 10:00

*Registration will be closed when it reaches the capacity.

In this meeting, RaQualia group’s R&D strategy including discovery phase programs will be explained. In addition, FIMECS’ platform technology and pipeline will be introduced. There will also be a Q&A session to discuss with you directly.

We look forward to seeing you there.

(Japanese only)

About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDSTM platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.

RaPPIDSTM (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform allows synthesizing and evaluating various degraders quickly based on the company’s proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target protein binders, linkers, and E3 ligase binders. Moreover, RaPPIDSTM platform enables the discovery of novel E3 ligase binders, which is expected to dramatically expand the range of target proteins that can be degraded.

Back to news list

Return to TOP